A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER

Trial Profile

A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER

Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Nimotuzumab (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Oncoscience
  • Most Recent Events

    • 06 Jun 2017 Results of overall survival estimation using a modified IPCW model presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2013 Primary endpoint 'Overall-survival' has been met.
    • 04 Jun 2013 Status changed from active, no longer recruiting to completed, according to presentation of results.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top